Leandro Cerchietti, October 13


SciLifeLab The Svedberg seminar series

Monday, October 13

Leandro Cerchietti

Weill Cornell Medical College, Cornell University, New York City, New York, USA.

Dr. Leandro Cerchietti is a Raymond and Beverly Sackler Scholar and Assistant Professor at Weill Cornell Medical College, Cornell University, New York City, New York, USA.

Epigenetic basis and targeted therapy of B-cell lymphomas

Epigenetic regulation is a fundamental process required by all cell types. Epigenetic marks form a biochemical language required to encode cellular phenotypes. Proteins that write, read and erase epigenetic instructions and the transcription factors that guide them play fundamental roles in normal B-cell development and lymphomagenesis. Aberrant epigenetic patterning, and somatic mutation of epigenetic modifier proteins, are hallmarks of B-cell lymphomas. In germinal center B-cells histone marks are dynamically controlled by transcription factors such as BCL6, and chromatin modifying proteins such as EZH2, MLL4 and CBP/EP300, which are perturbed in lymphomas. Lymphomas exhibit profound perturbations in cytosine methylation. DNA methylation heterogeneity occurs naturally in GC B-cells and is quite extreme in lymphomas, where it is linked to poor clinical outcome. Reversal of aberrant cytosine methylation in key pathways can induce chemo-sensitization of DLBCLs. Epigenetic therapy using inhibitors of BCL6, EZH2 and DNMTs is a promising new approach in lymphoma therapeutics.

Host: Richard Rosenqvist Brandell